TLR1 and cardiovascular disorder: Given the important role of TLR and PAR in cardiovascular disease [14, 68, 69], one may speculate that the stronger inhibitory effects of ticagrelor on TLR-1/2 and PAR mediated platelet activation compared to prasugrel may at least in part contribute to the beneficial impact of ticagrelor on all-cause mortality.